7R9A1980 - Copy.jpg

Ground-breaking digital health company Vitaccess is proud and excited to launch its brand new website. We’ve created a place for you to discover who we are, what we do and how we can help you. We’re continuing to add new features so you can stay informed about our work, our initiatives, and how we’re helping to advance understanding and treatment of disease.

We designed the Values and Corporate Responsibility pages to illustrate the principles that drive our work and our team spirit. Our About page introduces you to the Vitaccess team and lists the positions for which we’re currently recruiting. If a job description we’ve posted sounds like you, then we’d love to hear from you!

What makes Vitaccess unique is how we collaborate with patients/advocates and health care professionals. Our website includes content dedicated to both of those audiences so everyone can find the information that’s relevant for them.

In October 2017, we launched our Melanoma UK digital registry app, which now has over 360 users. The app is continually evolving, with recent updates adding a Knowledge Center, a Clinical Trials page, and a community feature. Watch our videos to find out what the patients have to say about the app.

Vitacess also collaborates with multiple patient advocacy organisations (PAOs) and biopharma sponsors to help patients in many countries who have rare diseases. One of our biopharma partners is clinical-stage company bluebird bio, which is conducting an international observational study of transfusion-dependent beta-thalassemia (TDT). TDT is a rare blood disease that can cause severe anemia and require frequent transfusions. The result of this partnership was the launch of myThalLog, a customized e-diary app for TDT patients, in August 2018. Patients use the app to record the impact of TDT on their daily lives. myThalLog is now live in the US and the UK and will soon be available in Germany, Italy and France.

September is Charcot-Marie-Tooth disease (CMT) awareness month and we are delighted to announce the launch of the CMT&Me app sponsored by Pharnext in October. To date there’s been little research exploring how CMT impacts the lives of patients with the disease. Pharnext, clinical experts, and PAOs have partnered to study the impact of the disease on patients’ daily lives. Vitaccess joined this collaboration to develop the CMT&Me app so patients can provide the information that researchers need. Watch this space as we’ll be announcing when the app is available in Google Play and the Apple store.

Our co-creation methodology wouldn’t be possible without the collaboration of diverse partners. We work with health professionals; biopharma companies, who sponsor our digital and HEOR and market access projects; and clinicians who serve on scientific advisory boards that oversee our digital projects. You can learn more about our data access arrangements for digital projects at our Professionals page. You can also learn about our experience in HEOR and market access, and read case studies that illustrate why Vitaccess is a trusted partner to the biopharma industry.

Our videos provide a great overview of what patients and professionals have to say about us. 

Please come on in and discover our culture of real-time, real-world evidence to help real people, #keepingitreal